Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms

References

• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARICE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BURICE, M. D. and MAYER, R. T., 1974, Ethoxyresorufin: direct fluorimetric assay of microsomal 0 - dealkylation which is preferentially induced by 3-methycholanthrene. Drug Metabolism and Disposition, 2, 583–588.
   PubMedGoogle Scholar
• CLARKE, S. E., AYRTON, A. D. and CHENERY, R. J., 1994, Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica, 24, 517–526.
   PubMed Web of Science ®Google Scholar
• GlERA, D. D. and VAN LlER, R. B. L., 1991, A convenient method for the determination of hepatic lauric acid co-oxidation based on solvent partition. Fundamental and Applied Toxicology, 16, 348–355.
   PubMedGoogle Scholar
• GONZALEZ, F. J., CRESPI, C. L. and GELBOIN, H. V., 1991, cDNA-expressed human cytochrome P-450s : a new age of molecular toxicology and human risk assessment. Mutation Research, 247, 113–127.
   PubMed Web of Science ®Google Scholar
• Ho, P., TRIGGS, E. J., HEAZLEWOOD, V. and BOURNE, D. W. A., 1983, Determination of nitrazepam and temazepam in plasma by high performance liquid chromatography. Therapeutic Drug Monitoring, 5, 303–307.
   PubMedGoogle Scholar
• KAWASHIMA, K., Hosoi, K., TAINAKA, H., SUBRAHMANYAM, V. V., NARUKE, T., SHIBA, T., KISHI, I. and WATABE, T., 1998, In vitro metabolism of CL284,846 using subcellular fraction of human liver. Drug Metabolism and Disposition (submitted).
   Google Scholar
• KRONBACH, T., 1991, Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6. Methods in Enzymology, 206, 509–517.
   PubMed Web of Science ®Google Scholar
• LAKE, B. G., 1987, Preparation and characterisation of microsomal fractions for studies of xenobiotic metabolism. In Biochemical Toxicology: A Practical Approach, edited by K. Snell and B. Mullock (Oxford: IRL), pp. 183–215.
   Google Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MEIER U. T., DAYER, P., MACE, P. J., KRONBACH, T. and MEYER, U. R., 1985, Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes from poor metabolizers phenotyped in vivo. Clinical Pharmacology and Therapeutics, 38, 488–494.
   Google Scholar
• NALINE, E., FLOUVAT, B., ADVENIER, C. and PAYS, M., 1987, Determination of theophylline and its metabolites in plasma and urine by reverse-phase liquid chromatography using an amine modifier. Journal of Chromatography, 419, 177–189.
   PubMed Web of Science ®Google Scholar
• NELSON D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., FSTABROOK, R. W., GUNSALUS I. C. and NEBERT D. W., 1996, P450 superfamily : update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1–42.
   Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GoNzALEz, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s : evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotka, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• PARKINSON, A., 1996a, An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicologic Pathology, 24, 45–57.
   Web of Science ®Google Scholar
• PARKINSON, A., 1996b, Biotransformation of xenobiotics. In Casarett and Doull' s Toxicology: The Basic Science of Poisons, 5th edn, edited by C. D. Klaassen (New York: McGraw Hill), pp. 113–186.
   Google Scholar
• PEARCE, R., GREENWAY, D. and PARKINSON, A., 1992, Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Archives of Biochemistry and Biophysics, 298, 211–225.
   PubMed Web of Science ®Google Scholar
• PETER, R., BoCKER, R., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. and YANG, C. S., 1990, Hydroxylation of chlorzoxazone as a specific probe for human cytochrome P-450I1E1. Chemical Research in Toxicology, 3, 566–573.
   PubMed Web of Science ®Google Scholar
• RODRIGUES, A. D., 1994, Comparison of levels of aldehyde oxidase with cytochrome P450 activities in human liver in vitro. Biochemical Pharmacology, 48, 197–200.
   PubMed Web of Science ®Google Scholar
• SCHWAB, G. E., RAUCY, J. L. and JOHNSON, E. F., 1988, Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by a-naphthoflavone. Molecular Pharma-cology, 33, 493–499.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., M1MURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   Google Scholar
• SONDERFAN, A. J., ARLOTTO, M. P., DUTTON, D. R., MCKILLEN, S. K. and PARKINSON, A., 1987, Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Drug Metabolism and Disposition, 255, 27–41.
   Google Scholar
• TASSANEEYAKUL W., BIRKETT, D. J., MuMANus, M. E., TASSANEEYAKUL W., VERONESE, M. E., ANDERSSON, T., TUKEY, R. H. and MINERS, J. O., 1994, Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochemical Pharmacology, 47, 1767–1776.
   PubMed Web of Science ®Google Scholar
• UENG, Y.-F., KUWABARA, T., CHuN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 36, 370–381.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A., VANDENBRANDEN, M., STEVENS, J. C., SHIPLEY, L. A., RING, B. J., RETTlE, A. E. and CASHMAN, J. R., 1993, In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metabolism Reviews, 25, 453–484.
   PubMed Web of Science ®Google Scholar